Tema Cardiovascular and Metabolic ETF
HRTS - ETF AI Analysis
Top Page
Tema Cardiovascular and Metabolic ETF (HRTS)
HRTS, the Tema Cardiovascular and Metabolic ETF, earns a solid overall rating driven by strong core holdings like Eli Lilly, Merck, Johnson & Johnson, and Gilead, which combine robust financial performance, attractive growth prospects, and supportive earnings outlooks. The fund’s score is held back somewhat by weaker names such as BridgeBio Pharma, where negative profitability and high leverage add risk, and by broader concerns like high valuations and leverage among several top positions. The main risk factor is its concentration in a specialized healthcare niche, where company-specific challenges or sector-wide setbacks could have an outsized impact on the ETF.
HRTS vs. SPDR S&P 500 ETF (SPY)
- AUM
- 57.71M
- Region
- Global
- Expense Ratio
- 0.75%
- Beta
- 0.60
- Issuer
- Tema
- Inception Date
- Nov 21, 2023
- Dividend Yield
- 1.21%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
HRTS Summary
The Tema Cardiovascular and Metabolic ETF (HRTS) is a health care fund focused on companies working on heart disease, diabetes, and other metabolic conditions, mainly in the U.S. It does not track a traditional index, but instead follows a theme of pharma, biotech, and life sciences firms driving new treatments and medical technologies. Well-known holdings include Eli Lilly and Johnson & Johnson. Someone might invest in HRTS for growth potential from medical innovation and to get targeted exposure to leading health care companies. A key risk is that it is heavily concentrated in one sector, so its value can rise or fall sharply with health care stocks.
How much will it cost me?
This ETF has an expense ratio of 0.75%, which means you’ll pay about $7.50 per year for every $1,000 invested. That’s higher than the average ETF because it’s actively managed and focused on a specialized niche in cardiovascular and metabolic health, which typically costs more to run than broad, passive index funds.
What would affect this ETF?
HRTS could benefit from growing global demand for treatments for heart disease and diabetes, successful new drug approvals from major holdings like Eli Lilly, Merck, and Johnson & Johnson, and continued innovation in biotech and life sciences. On the negative side, it is heavily concentrated in health care, so tighter drug pricing rules, regulatory setbacks, or changes in insurance and reimbursement policies around the world could hurt the fund’s companies and weigh on future returns.
HRTS Top 10 Holdings
HRTS is leaning heavily on health care powerhouses, with Eli Lilly acting as the fund’s engine thanks to its rising momentum in diabetes and obesity treatments. Thermo Fisher, Roche, and Johnson & Johnson add steady, broadly rising support, giving the portfolio a solid backbone of established global names. On the flip side, Revolution Medicines and Kodiak Sciences bring high‑octane biotech potential but also inject volatility, sometimes dragging on short‑term results. Overall, this is a globally focused, cardiometabolic‑themed fund, concentrated in health care and tilted toward a mix of blue-chip stability and speculative biotech upside.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 12.63% | $7.29M | $1.36T | 41.12% | 72Outperform | |
| Thermo Fisher | 5.31% | $3.06M | $259.44B | 20.70% | 72Outperform | |
| Roche Holding | 4.32% | $2.49M | $384.64B | 32.47% | 74Outperform | |
| Merck & Company | 4.19% | $2.42M | $364.26B | 59.00% | 80Outperform | |
| Kodiak Sciences | 4.05% | $2.34M | $7.27B | 489.24% | 35Underperform | |
| BridgeBio Pharma | 3.69% | $2.13M | $15.25B | 20.35% | 59Neutral | |
| Gilead Sciences | 3.39% | $1.96M | $208.48B | 34.25% | 78Outperform | |
| Revolution Medicines | 3.26% | $1.88M | $37.27B | 167.61% | 52Neutral | |
| Danaher | 3.10% | $1.79M | $163.94B | 5.34% | 75Outperform | |
| Johnson & Johnson | 2.87% | $1.66M | $687.89B | 46.35% | 78Outperform |
HRTS Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For HRTS, the sentiment is Positive. The current price of 39.24 is above the 20-day moving average (MA) of 38.42, above the 50-day MA of 37.15, and above the 200-day MA of 35.70, indicating a bullish trend. The MACD of 0.65 indicates Negative momentum. The RSI at 60.54 is Neutral, neither overbought nor oversold. The STOCH value of 61.23 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HRTS.
HRTS Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $39.24 | $40.00(1.93% Upside) | $57.71M | 0.75% | 67Neutral | |
| $31.42 | $48.37(53.98% Upside) | $57.30M | 0.59% | 57Neutral | |
| $36.34 | $46.47(27.90% Upside) | $44.15M | 0.80% | 62Neutral | |
| $19.23 | $58.19(202.59% Upside) | $41.90M | 1.00% | 44Neutral | |
| $34.80 | $54.70(57.19% Upside) | $41.60M | 0.44% | 60Neutral | |
| $39.33 | $44.91(14.20% Upside) | $20.55M | 0.75% | 71Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HRTS | Tema Cardiovascular and Metabolic ETF | 39.24 | 5.31 | 15.65% | |
| OZEM | Roundhill GLP-1 & Weight Loss ETF | 31.41 | -0.42 | -1.31% | |
| MEDI | Harbor Health Care ETF | 36.34 | 4.91 | 15.61% | |
| PSIL | AdvisorShares Psychedelics ETF | 19.23 | 2.77 | 16.80% | |
| TMED | T. Rowe Price Health Care ETF | 34.80 | 5.80 | 19.98% | |
| GDOC | Goldman Sachs Future Health Care Equity ETF | 39.33 | 3.63 | 10.17% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
